SN-38

Catalog No.S4908 Synonyms: NK012

For research use only.

SN-38 (NK012) is an active metabolite of CPT-11, inhibits DNA topoisomerase I, DNA synthesis and causes frequent DNA single-strand breaks. SN-38 induces autophagy.

SN-38 Chemical Structure

CAS No. 86639-52-3

Selleck's SN-38 has been cited by 42 publications

Purity & Quality Control

Choose Selective ADC Cytotoxin Inhibitors

Biological Activity

Description SN-38 (NK012) is an active metabolite of CPT-11, inhibits DNA topoisomerase I, DNA synthesis and causes frequent DNA single-strand breaks. SN-38 induces autophagy.
Targets
Topo I [1]
(Cell-free assay)
In vitro

SN-38, a biological active metabolite of irinotecan hydrochloride (CPT-11). SN-38 causes the strongest inhibition of DNA topoisomerase I, followed by CPT and then CPT-11. CPT-11 dose dependently shifts the position of relaxed DNA in the direction of nicked DNA, but SN-38 and CPT shows no effect on the position of relaxed DNA. SN-38 dose-dependently and time-dependently inhibit DNA synthesis. Respective IC50 values of SN-38, in DNA synthesis is 0.077 μM. The inhibitory effect of SN-38 on RNA synthesis is less than that on DNA synthesis and it does not inhibit protein synthesis. SN-38 caused frequent DNA single-strand breaks in P388 cells. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human DU145 prostate cell line NGDzdpFRem:uaX\ldoF1cW:wIHHzd4F6 NUOyfnF4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDEWVE1PSCycn;zeIF1\SClZXzsJIxqdmVuIFnDOVA:OTNibl2= MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODR7OEKxOkc,OTB2OUiyNVY9N2F-
human MCF-7 breast cell line NED1XnVRem:uaX\ldoF1cW:wIHHzd4F6 M37HRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGMVch[nKnYYP0JINmdGxibHnu[UwhUUN3ME2wMlM4KM7:TR?= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODR7OEKxOkc,OTB2OUiyNVY9N2F-
human SKOV-3 ovarian cell line NVHtd4JHWHKxbHnm[ZJifGmxbjDhd5NigQ>? M4X6cmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1vPWk0{KG:4YYLpZY4h[2WubDDsbY5mNCCLQ{WwQVAvPzJizszN M1fsR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyNEm4NlE3Lz5zMES5PFIyPjxxYU6=
human breast cancer cell line (SK-BR-3) M4HsOWN6fG:2b4jpZ:Kh[XO|YYm= M3jROmlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIJz\WG|dDDjZY5k\XJiY3XscEBtcW6nIDjTT{1DWi1|KTygTWM2OD12IH7N NXyzeI1bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzN|Q2PjlpPkGxN|M1PTZ7PD;hQi=>
human lung cancer cell line (H128) MYXDfZRwfG:6aXRCpIF{e2G7 NH:zXVBKdiCYaYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBtfW6pIHPhcoNmeiClZXzsJIxqdmViKFixNlgqNCCLQ{WwQVYhdk1? Mlr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF|M{S1OlkoRjFzM{O0OVY6RC:jPh?=
human stomach cancer cell line (MKN45) NIjIVnBEgXSxdH;4bYPDqGG|c3H5 MnPFTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gd5RwdWGlaDDjZY5k\XJiY3XscEBtcW6nIDjNT241PSluIFnDOVA:QCCwTR?= M4LZN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{O0OVY6Lz5zMUOzOFU3QTxxYU6=
human ovarian cancer cell line (SK-OV-3) MnLsR5l1d3SxeHnjxsBie3OjeR?= M1n6eWlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI93[XKrYX6gZ4Fv[2W{IHPlcIwhdGmwZTCoV2suV1ZvMzmsJGlEPTB;MUGgcm0> NGrUXmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOzOFU3QSd-MUGzN|Q2Pjl:L3G+
human colon cancer cell line (WiDr) M1KwSmN6fG:2b4jpZ:Kh[XO|YYm= MYjJckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDjc4xwdiClYX7j[ZIh[2WubDDsbY5mKCiZaVTyLUwhUUN3ME2xOEBvVQ>? MoDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF|M{S1OlkoRjFzM{O0OVY6RC:jPh?=
human lung cancer cell line (A549) M4XKW2N6fG:2b4jpZ:Kh[XO|YYm= M37afGlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIx2dmdiY3HuZ4VzKGOnbHygcIlv\SBqQUW0PUk> NXfZepFORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzN|Q2PjlpPkGxN|M1PTZ7PD;hQi=>
NSCLC-H460 MV;DfZRwfG:6aXRCpIF{e2G7 M2\yOmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJI5wdi2|bXHscE1k\WyuIHz1coch[2G{Y3nuc41iKGOnbHygcIlv\SCKNE[wJEhPW0OOQz3IOFYxMSxiSVO1NF05OCCwTR?= NFf2R4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUW2N|kzPSd-MUG1OlM6OjV:L3G+
PC-3 carcinoma cell line NWnyZppVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHizO2REd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSg[5Jwf3SqIH;mJIh2dWGwIIDyc5N1[XSnIGDDMVMh[2G{Y3nuc41iKGOnbHygcIlv\SxiSVO1NF0{PS54IH7N MnPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV2NUSyN|AoRjF3NEW0NlMxRC:jPh?=
human HCT116 colon cancer cell line NEDKU4pHfW6ldHnvckBie3OjeR?= MXLJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCqdX3hckBJS1RzMU[gZ49td25iY3HuZ4VzKGOnbHygcIlv\SxiSVO1NF04KG6P MlqzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV6MEi0OVYoRjF3OEC4OFU3RC:jPh?=
human Bel-7402 liver cancer cell line MmHtSpVv[3Srb36gZZN{[Xl? M{nTRWlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IHj1cYFvKEKnbD23OFAzKGyrdnXyJINidmOncjDj[YxtKGyrbnWsJGlEPTB;Mz6xPUDPxE1? NWn6WGw5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW4NFg1PTZpPkG1PFA5PDV4PD;hQi=>
human tumor HL60 cell-line MWfGeY5kfGmxbjDhd5NigQ>? MlT0N{Bl[Xm| MYHJck13cXS{bzDpcohq[mm2b4L5JINwdmOnboTyZZRqd25iZn;yJIh2dWGwIIT1cY9zKEiONkCgZ4VtdC2uaX7lJJdieyCmZYTldo1qdmWmIIXzbY5oKFOUQjDhd5NigSCjZoTldkA{KGSjeYOgc4YhcW6ldXLheIlwdixiSVO1NF0yQSCwTR?= MknLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV7MUO5PVYoRjF3OUGzPVk3RC:jPh?=
human H460 cell M33iWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGjMb|VKdmirYnn0bY9vKG:oIHj1cYFvKEh2NkCgZ4VtdCCpcn;3eIgtKEmFNUC9PFAhdk1? NGnRVlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkmxN|cxPid-MU[5NVM4ODZ:L3G+
MDA-MB-435 M4DGPWZ2dmO2aX;uJIF{e2G7 NFnqOIhKdmirYnn0bY9vKGGpYXnud5QhVUSDLV3CMVQ{PSCVIHj1cYFvKGK{ZXHzeEBk[W6lZYKgZ4VtdHNiaX6geIhmKGGkc3XuZ4Uhd2ZiYXzieY1qdixiSVO1NEA:KDBwMEC1JO69VS5? NY[4TnlTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGwOVI5ODJpPkGxNFUzQDB{PD;hQi=>
MDA-MB-435 MX\GeY5kfGmxbjDhd5NigQ>? MnraTY5pcWKrdHnvckBi\2GrboP0JG1FSS2PQj20N|UhWyCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIx{KGmwIITo[UBxemW|ZX7j[UBw\iB|MDDt[{9uVCCKU1GsJGlEPTBiPTCwMlA2KM7:TT6= MlrDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTFyNUK4NFIoRjFzMEWyPFAzRC:jPh?=
PC-6/SN2-5H NVjvbppwTnWwY4Tpc44h[XO|YYm= MmTGWHBgXFKDTmPQU3JVTVJ8IIXweIFs\SCrbjDt[Y1jemGwZTD2[ZNq[2ynIH\yc40hWENvNj;TUlIuPUhiY3XscJMtKEuvIE2gOEDPxE1w NHzRW2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMU[4PFk5Oid-MUG2PFg6QDJ:L3G+
HT-29 NETSZ4lHfW6ldHnvckBie3OjeR?= MYPJckB3cXS{bzDpcohq[mm2b4L5JINwdmOnboTyZZRqd25icnXxeYlz\WRiYXfhbY5{fCCKVD2yPUBpfW2jbjDjc4xwdiClYX7j[ZIh[2WubIOsJGlEPTBiPTCwMlAzPzNizszNMi=> M3OxXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NkG3PVI4Lz5zMk[xO|kzPzxxYU6=
SaoS2 NGrLdGRHfW6ldHnvckBie3OjeR?= NF[yT2pVWF:WUlHOV3BQWlSHUkqg[JJ2\yC{ZYPpd5RidmOnKFntZZRqdmmkIH3ld5lt[XSnKTDpckBDS1KSLXX4dJJme3OrbnegV4FwWzJiY3XscJMtKEmFNUCgQUAxNjF5NjFOwG0v MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTB3OUi4NUc,OTVyNUm4PFE9N2F-
DU145 NF72UFhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NUTqWnJ4QTZiaILz NHLG[GZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTVNVQ2KGOnbHzzJIFnfGW{IEm2JIhzeyxiSVO1NEA:KDBwMEC0JO69VS5? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ5NkG0NUc,OTh{N{[xOFE9N2F-
MIA PaCa MkjHRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MWe5OkBpenN? M4DwPGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVnBJHBiS2FiY3XscJMh[W[2ZYKgPVYhcHK|LDDJR|UxKD1iMD6wNFYh|ryPLh?= MoDlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{N{[xOFEoRjF6Mke2NVQyRC:jPh?=
HT29 MVzBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NHLBfWI6PiCqcoO= MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWMkmgZ4VtdHNiYX\0[ZIhQTZiaILzMEBKSzVyIE2gNE4xOTJizszNMi=> M4TZW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Mke2NVQyLz5zOEK3OlE1OTxxYU6=
H460 M3HOWGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MXmxJIhz NUKydmtZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIOFYxKGOnbHzzJIFnfGW{IEGgbJIhd2ZiZIL1[{BmgHCxc4Xy[UBu\WG|dYLl[EBi\nSncjC3NkBpenNuIFnDOVAhRSByLkKyJO69VS5? NX\ucHRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0NlQyOzNpPkG4OFI1OTN|PD;hQi=>
HT29 MkH6RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NHTHfpgyKGi{ NYHFcWplSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWFI6KGOnbHzzJIFnfGW{IEGgbJIhd2ZiZIL1[{BmgHCxc4Xy[UBu\WG|dYLl[EBi\nSncjC3NkBpenNuIFnDOVAhRSByLk[3JO69VS5? NUPsb|RZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0NlQyOzNpPkG4OFI1OTN|PD;hQi=>
HT29 NGSxR3VCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MoXrNUBpeg>? NXXUT3dCSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBDS1KSIH;2[ZJmgHC{ZYPzbY5oKG2rdH;4ZY51em:wZT3y[ZNqe3SjboSgbJVu[W5iSGSyPUBk\WyuczDh[pRmeiBzIHjyJI9nKGS{dXeg[Zhxd3O3cnWgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOTFwNTFOwG0v Mk[yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2MkSxN|MoRjF6NEK0NVM{RC:jPh?=
H460 M1LCcWN6fG:2b4jpZ4l1gSCjc4PhfS=> MofFR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFQ3OCClZXzsd{whUUN3MDC9JFAvOjJizszNMi=> NIG3S2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOESzOFE2Oyd-MUi0N|QyPTN:L3G+
A549 M3zW[2N6fG:2b4jpZ4l1gSCjc4PhfS=> M162[WN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[nliU2LCJI1mfGixZDygTWM2OCB;IECuNFgh|ryPLh?= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl6NkiwO{c,OTh7OE[4NFc9N2F-
HT-29 NF\Ib|REgXSxdH;4bYNqfHliYYPzZZk> NEC3fZREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCkeTDTVmIhdWW2aH;kMEBKSzVyIE2gNE4yOiEQvF2u MlP5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7OE[4NFcoRjF6OUi2PFA4RC:jPh?=
PC6 M1yw[mFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M3rDR|Yh\GG7cx?= MmLyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{[gZ4VtdHNiY3HydplqdmdicGLDJIFnfGW{IE[g[IF6eyxiSVO1NEA:KDBwMECwOFMh|ryPLh?= MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ3NEi0N{c,OTl{NUS4OFM9N2F-
HCT116 MonuRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MkLjN{Bl[Xm| Ml7uRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiMzDkZZl{NCCLQ{WwJF0hOC5yMEC1OUDPxE1w MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ3NEi0N{c,OTl{NUS4OFM9N2F-
QG56 NVLIUFlMSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NX7nR2h{OyCmYYnz M3[0cGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUVe1OkBk\WyuczDh[pRmeiB|IHThfZMtKEmFNUCgQUAxNjByMkig{txONg>? MkT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{NUS4OFMoRjF7MkW0PFQ{RC:jPh?=
NCI-H460 NHLqfIlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MYWzJIRigXN? NVm5Xnp7SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxteyCjZoTldkA{KGSjeYOsJGlEPTBiPTCwMlAxOzNizszNMi=> NXXrPW9DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyOVQ5PDNpPkG5NlU1QDR|PD;hQi=>
BCRP NX;yT3NiSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NGX6U5c3KGSjeYO= M2GwVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFO2JIV5eHKnc4PpcochSkOUUDDj[YxteyCjZoTldkA3KGSjeYOsJGlEPTBiPTCwMlAxPTFizszNMi=> NFXN[pQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUK1OFg1Oyd-MUmyOVQ5PDN:L3G+
KB3-1 MUfDfZRwfG:6aXPpeJkh[XO|YYm= MkTjOEBl[Xm| MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRlMuOSClZXzsd{Bi\nSncjC0JIRigXNiYomgUXRVKG2ndHjv[EwhUUN3MDC9JFAvODB2IN88UU4> Mn\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl|MEOzNFYoRjF7M{CzN|A3RC:jPh?=
KBV1 NFj2NYlEgXSxdH;4bYNqfHliYYPzZZk> MXy0JIRigXN? M1ThZ2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KE2GUkGgc5ZmemW6cILld5NqdmdiaIXtZY4hU0KYMTDj[YxteyCjZoTldkA1KGSjeYOgZpkhVVSWIH3leIhw\CxiSVO1NEA:KDBwMES2JO69VS5? MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTNyM{OwOkc,OTl|MEOzNFY9N2F-
KBH5.0 Mlv1R5l1d3SxeHnjbZR6KGG|c3H5 M4qzdlQh\GG7cx?= NGn4UJJEgXSxdH;4bYNqfHliYXfhbY5{fCCEQ2LQJI93\XKneIDy[ZN{cW6pIHj1cYFvKEuESEWuNEBk\WyuczDh[pRmeiB2IHThfZMh[nliTWTUJI1mfGixZDygTWM2OCB;IECuN{DPxE1w NEO1VXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUOwN|MxPid-MUmzNFM{ODZ:L3G+
NCI-H460 NH;wUWFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NF\2UHIyKGi{ MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IOFYxKGOnbHzzJIFnfGW{IIPoc5J1KHSncn2g[Zhxd3O3cnWg[o9zKDFiaIKgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGmwIHTyeYcu\nKnZTDt[YRqfW1uIFnDOVAhRSByLkGzJO69VS5? M1m1VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUOwO|IxLz5zOUWzNFczODxxYU6=
A549/ATCC M4m3cGFvfGm2dX3vdkBie3OjeR?= MX;BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDNUS5M2FVS0NiY3XscJMh[nliU2LCJI1mfGixZDygTWM2OCB;IECuNFg5KM7:TT6= NGSzcG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUW0NVQ5Oyd-MUm1OFE1QDN:L3G+
HT-29 NUnFOVVJSW62aYT1cY9zKGG|c3H5 MUXBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVD2yPUBk\WyuczDifUBUWkJibXX0bI9lNCCLQ{WwJF0hOC5zNzFOwG0v MkPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3NEG0PFMoRjF7NUSxOFg{RC:jPh?=
gastric cancer cells MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEHGN4c4OiCqcoO= NF3oU41Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBo[XO2cnnjJINidmOncjDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygS2k2OCB;IECuNFY3KM7:TT6= MkHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OESwPFkoRjJyOEi0NFg6RC:jPh?=
lung cancer cells M2KxTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHzXOoE4OiCqcoO= MWTHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDseY5oKGOjbnPldkBk\WyuczDh[pRmeiB5MjDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhT0l3MDC9JFAvODZ4IN88UU4> MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6NEC4PUc,OjB6OESwPFk9N2F-
colon cancer cells MnPHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVW3NkBpenN? NX7FZ4tbT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[2:ub36gZ4Fv[2W{IHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDHTVUxKD1iMD6wOlYh|ryPLh?= M2nIc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEi0NFg6Lz5{MEi4OFA5QTxxYU6=
HT-29 NIHoZ2REgXSxdH;4bYNqfHliYYPzZZk> MlPNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMtKEmFNUCgQUAxNjByNUmg{txONg>? M4fkNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEewPFY1Lz5{MUS3NFg3PDxxYU6=
A549 NFT2ZlBEgXSxdH;4bYNqfHliYYPzZZk> MV;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzMEBKSzVyIE2gNE4xPDdizszNMi=> NYnRdnpiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0O|A5PjRpPkKxOFcxQDZ2PD;hQi=>
PC3 MV;DfZRwfG:6aXPpeJkh[XO|YYm= MVy3NkBpenN? MnjhR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIV5eHKnc4Ppcoch[WyyaHG1ZoV1[TNiaX70[YdzcW5iYYPz[ZN{\WRiYYOgZ4VtdCC|dYL2bZZidCCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5yMEK2JO69VS5? M1y1WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUW5NlQ3Lz5{Mkm1PVI1PjxxYU6=
A2780 NYmy[YpkS3m2b4TvfIlkcXS7IHHzd4F6 M1S5UlczKGi{cx?= NEG3fWtEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCxdnXy[ZhxemW|c3nu[{BidHCqYUXi[ZRiOyCrboTl[5JqdiCjc4Pld5Nm\CCjczDj[YxtKHO3co\peoFtKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjByOTFOwG0v MlvtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NUmyOFYoRjJ{OUW5NlQ3RC:jPh?=
DU145 MY\DfZRwfG:6aXPpeJkh[XO|YYm= NYP5OWx2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNuIFnDOVAhRSByLkCzJO69VS5? MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV5OEW0OUc,OjN3N{i1OFU9N2F-
HT-29 NHHWcGtEgXSxdH;4bYNqfHliYYPzZZk> MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{whUUN3MDC9JFAvODNizszNMi=> M1vOSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUe4OVQ2Lz5{M{W3PFU1PTxxYU6=
L1210 NXzrXFYyS3m2b4TvfIlkcXS7IHHzd4F6 NE\2eGpEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBNOTJzMDDj[YxteyxiSVO1NEA:KDBwMESg{txONg>? NH;0[Vg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W3PFU1PSd-MkO1O|g2PDV:L3G+
DU145 NXywd291S3m2b4TvfIlkcXS7IHHzd4F6 MkHsO|IhcHK| MWDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLkGxJO69VS5? NVrTWVJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NlI6QDFpPkKzOlIzQThzPD;hQi=>
DU145 MmTwSpVv[3Srb36gZZN{[Xl? NUXaRWRZOC5zIITvJFAvPSC3TR?= NVfyVlY3OjRiaILz NYnPc5QyUW6qaXLpeIlwdiCxZjDISGFEKGmwIHj1cYFvKESXMUS1JINmdGy|IHHzd4V{e2WmIHHzJJVxemWpdXzheIlwdiCxZjDwNlF4[WZzIHX4dJJme3Orb36gZZQhOC5zIITvJFAvPSC3TTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz MnLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MkK5PFEoRjJ|NkKyPVgyRC:jPh?=
A549 NHnDe5FEgXSxdH;4bYNqfHliYYPzZZk> M4PpVlMh\GG7cx?= M3;P[WN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhOyCmYYnzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDBwMECyO|Ih|ryPLh?= NYi0eYdnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1Nlk5PzBpPkK0OVI6QDdyPD;hQi=>
HCT116 NVPmcotiS3m2b4TvfIlkcXS7IHHzd4F6 MVizJIRigXN? M{SyXGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB|IHThfZMh[nliU2LCJIF{e2G7LDDJR|UxKD1iMD6wN|Eh|ryPLh?= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV{OUi3NEc,OjR3Mkm4O|A9N2F-
HT-29 MVfDfZRwfG:6aXPpeJkh[XO|YYm= NV:zOJN[OyCmYYnz MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA{KGSjeYOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5zME[2O{DPxE1w NWTke5Z2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1Nlk5PzBpPkK0OVI6QDdyPD;hQi=>
HCT116 NGSxcGNEgXSxdH;4bYNqfHliYYPzZZk> NG\wRo1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNuIFnDOVAhRSByLkG2OkDPxE1w NW\uRZFURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1Nlk5PzBpPkK0OVI6QDdyPD;hQi=>
MDA-MB-231 NUKxR3pKS3m2b4TvfIlkcXS7IHHzd4F6 MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|LDDJR|UxKD1iMD6xO|Yh|ryPLh?= NV\DR2hjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1Nlk5PzBpPkK0OVI6QDdyPD;hQi=>
A549 Mnm2R5l1d3SxeHnjbZR6KGG|c3H5 MWDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzMEBKSzVyIE2gNE4zPTlizszNMi=> M3L1d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUK5PFcxLz5{NEWyPVg4ODxxYU6=
HEK293 MX7DfZRwfG:6aXPpeJkh[XO|YYm= MlT4O|IhcHK| MlnRTY51emmwc3njJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUd3MDC9JFAvODB3IN88UU4> MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MkC1OUc,OjV{N{KwOVU9N2F-
HCT116 MXLDfZRwfG:6aXPpeJkh[XO|YYm= NH35Zpo4OiCqcoO= MnT3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDJR|UxKD1iMD6wNFQzQCEQvF2u NVTOVmlpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N|U{PTlpPkK1PFM2OzV7PD;hQi=>
HT-29 M4jJPWN6fG:2b4jpZ4l1gSCjc4PhfS=> M4\YXlczKGi{cx?= NEixfm5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygTWM2OCB;IECuNFE5PTRizszNMi=> M371c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO1N|U6Lz5{NUizOVM2QTxxYU6=
HCT15 NILMV4hEgXSxdH;4bYNqfHliYYPzZZk> M1\6W|czKGi{cx?= NVfveWFiS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUWgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFA5KM7:TT6= M2nldlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[wO|YxLz5{N{C2NFc3ODxxYU6=
U251 M13udWN6fG:2b4jpZ4l1gSCjc4PhfS=> MXi3NkBpenN? NF2zfI9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWOjVzIHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSByLkCyNUDPxE1w NXL2cJpERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewOlA4PjBpPkK3NFYxPzZyPD;hQi=>
U87MG MYfDfZRwfG:6aXPpeJkh[XO|YYm= Mk\KO|IhcHK| M{D0[WN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHU5P02JIHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSByLkCzJO69VS5? Moj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyNkC3OlAoRjJ5ME[wO|YxRC:jPh?=
HT-29 MXrDfZRwfG:6aXPpeJkh[XO|YYm= NFPBZ4w4OiCqcoO= NVvOdWhYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFU1KM7:TT6= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB4MEe2NEc,OjdyNkC3OlA9N2F-
MCF7 NXq5VIlxS3m2b4TvfIlkcXS7IHHzd4F6 M2C1XFczKGi{cx?= MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjVzNTFOwG0v NVqzTFZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewOlA4PjBpPkK3NFYxPzZyPD;hQi=>
MDA-MB-231 MX3DfZRwfG:6aXPpeJkh[XO|YYm= NU\kPWRvPzJiaILz M{XjXmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|IhcHK|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFEvQTdizszNMi=> Mn3DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyNkC3OlAoRjJ5ME[wO|YxRC:jPh?=
NCI-H460 MXrDfZRwfG:6aXPpeJkh[XO|YYm= NFfJZ2EzPCCqcoO= MV;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxteyCycnX0doVifGWmIH\vdkAzPCCqcoOgeY5l\XJibn;ycY95cWNiY3;u[Il1cW:wIH\vcIxwf2WmIHL5JINwdXCxdX7kJJdie2ixdYSgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFUh|ryPLh?= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN3MEm5O{c,Ojh|NUC5PVc9N2F-
NCI-H460 M3TP[WN6fG:2b4jpZ4l1gSCjc4PhfS=> MnfyNlQhcHK| MlPZR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNicILleJJm[XSnZDDmc5IhOjRiaILzJJVv\GW{IHj5dI95cWNiY3;u[Il1cW:wIH\vcIxwf2WmIHL5JINwdXCxdX7kJJdie2ixdYSgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFYh|ryPLh?= NFrFN|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO1NFk6Pyd-MkizOVA6QTd:L3G+
HT-29 MofaR5l1d3SxeHnjbZR6KGG|c3H5 Mk\aNlQhcHK| M2Ti[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{KHC{ZYTy[YF1\WRiZn;yJFI1KGi{czD1coRmeiCwb4Ltc5hq[yClb37kbZRqd25iZn;scI94\WRiYomgZ49ueG:3bnSge4F{cG:3dDDt[YF{fXKnZDDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMj63OEDPxE1w M1K3blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{WwPVk4Lz5{OEO1NFk6PzxxYU6=
HT-29 M{DkcWN6fG:2b4jpZ4l1gSCjc4PhfS=> MkC5NlQhcHK| MnrQR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMheHKndILlZZRm\CCob4KgNlQhcHK|IIXu[IVzKGi7cH;4bYMh[2:wZHn0bY9vKG[xbHzve4VlKGK7IHPvcZBwfW6mIIfhd4hwfXRibXXhd5Vz\WRiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDNwN{Gg{txONg>? M1jLfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{WwPVk4Lz5{OEO1NFk6PzxxYU6=
NCI-H460 M3HlOmN6fG:2b4jpZ4l1gSCjc4PhfS=> MojFO|IhcHK| NGTJelJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSES2NEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigdoVlfWO2aX;uJJVv\GW{IHj5dI95cWNiY3;u[Il1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkC0O{DPxE1w NW\B[ppbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OFA3OTNpPkK4O|QxPjF|PD;hQi=>
NCI-H460 NHTsV2VEgXSxdH;4bYNqfHliYYPzZZk> NXrmcZhLPzJiaILz MnjoR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIILl[JVkfGmxbjD1coRmeiCwb4Ltc5hq[yClb37kbZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEWg{txONg>? MkXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5NEC2NVMoRjJ6N{SwOlE{RC:jPh?=
HT-29 NHnrN|ZEgXSxdH;4bYNqfHliYYPzZZk> MVK3NkBpenN? MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghemWmdXP0bY9vKHWwZHXyJI5wem2xeHnjJINwdmSrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE4xQTZizszNMi=> NFvOZng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEe0NFYyOyd-Mki3OFA3OTN:L3G+
HT-29 MmDSR5l1d3SxeHnjbZR6KGG|c3H5 MoKwO|IhcHK| Mlm4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKHKnZIXjeIlwdiC3bnTldkBpgXCxeHnjJINwdmSrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE4yOTlizszNMi=> M1q3R|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{SwOlE{Lz5{OEe0NFYyOzxxYU6=
TC32 NYf2bVh{eUiWUzDhd5NigQ>? MlnCdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN? MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 M1HQbJFJXFNiYYPzZZk> NHrUOVFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= NF7QTGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
DAOY MYXxTHRUKGG|c3H5 MlL4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? M3TVbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2 MYrxTHRUKGG|c3H5 NGDn[XlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz NHTuUW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 NFLtbmhyUFSVIHHzd4F6 MVfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? M2OwRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD NUmz[XBDeUiWUzDhd5NigQ>? NILMSVByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN? MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH MnizdWhVWyCjc4PhfS=> M{HJNZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz NVnXR5lTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 Ml6wdWhVWyCjc4PhfS=> NH;jOWpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO= MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) M1TCTpFJXFNiYYPzZZk> NGrybm1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO= NFTFd|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 MoXidWhVWyCjc4PhfS=> MkfidWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?= M1Gx[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 MVnxTHRUKGG|c3H5 MoHndWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= NIXXPHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-12 NFnpN5RyUFSVIHHzd4F6 M{e2fJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTF{IHPlcIx{ MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 NFrOfIZyUFSVIHHzd4F6 M3nBRpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy| M4PMZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 M17WPZFJXFNiYYPzZZk> MlTxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIuTUKlMTDj[Yxtew>? MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH M3jZUpFJXFNiYYPzZZk> NHXkN2hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLWPIJINmdGy| NWjpUVhwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30 M2DafpFJXFNiYYPzZZk> NV7CeI1meUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoN|Ah[2WubIO= M3nKflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 M1vmVpFJXFNiYYPzZZk> M2XHW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh30 NFfMdZlyUFSVIHHzd4F6 M2WxeJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOzBiY3XscJM> NWHhbnFxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS MWjxTHRUKGG|c3H5 NEX1OmNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN? MkSxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 MUnxTHRUKGG|c3H5 NVH1So9yeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? MkL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 MXzxTHRUKGG|c3H5 NHrTUlNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC NE\YSpRyUFSVIHHzd4F6 MXjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= MoL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1 NWDxPGRWeUiWUzDhd5NigQ>? M2LGbpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz NXWyS5p6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 MYTxTHRUKGG|c3H5 NEC3fopyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO= M3PVVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18 NEfBO3lyUFSVIHHzd4F6 MUfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>? NGHlXnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
HCT116 MUfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NUfTbFVGPzJiaILz Mn74RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFAxPzhizszNMi=> MlzzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzMUW0PVIoRjNyMUG1OFkzRC:jPh?=
A549 NGfk[WtCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MnTYO|IhcHK| MX7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDBwMECxOlIh|ryPLh?= NYjrRVdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxNVU1QTJpPkOwNVE2PDl{PD;hQi=>
MCF7 M1;OWWN6fG:2b4jpZ4l1gSCjc4PhfS=> MXm3NkBpenN? MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCLQ{WwJF0hOC5yMECxJO69VS5? MorkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzNkmwN|goRjNyMU[5NFM5RC:jPh?=
A549 MUDDfZRwfG:6aXPpeJkh[XO|YYm= MlzBO|IhcHK| Mo\6R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiSVO1NEA:KDBwMjFOwG0v M3PpSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMU[5NFM5Lz5|MEG2PVA{QDxxYU6=
Assay
Methods Test Index PMID
Western blot p-Chk1 / Chk1 / Topo I 18509065
Growth inhibition assay Cell viability 25759163
In vivo After oral dosing, peak SN-38 concentrations occurrs within 1 h, and the The percent unbound SN-38 lactone in murine plasma at 1000 ng/mL is 3.4 +/- 0.67%, whereas at 100 ng/mL the percent unbound is 1.18 +/- 0.14%. SN-38 lactone AUCs in micebearing human neuroblastoma xenografts are greater than in nontumor-bearing animals. [2]

Protocol (from reference)

Kinase Assay:[1]
  • Topoisomerase I Assay:

    One unit (the minimum amount for full relaxation of 0.5 μg SV40 DNA under the conditions of this study) of topoisomerase I, 0.5 μL of the test compounds, and 0.5μg SV40 DNA are added sequentially to the reaction buffer, which is composed of 25 mM Tris-HCl (pH 7.5), 50 mM KC1, 5 mM MgCl2, 0.25 mM EDTA disodium salt, 0.25 mM dithiothreitol, 15μg /mL bovine serum albumin, and 5% glycerol. Then, the reaction mixture (50 μL) is incubated for 10 min at 37 °C, and the reaction is terminated by treatment with 7.5 μL of a solution consisting of 1% sodium dodecyl sulfate, 20 mM EDTA disodium salt, and 0.5 mg/mL proteinase K for an additional 30 min at 37°C. The samples are mixed with 5 μL of the loading buffer containing 10 mM Na2HPO4, 31.3% sucrose, and 0.3% bromophenol blue. Relaxed (form Ir) DNA is separated from supercoiled (form I) and nicked (form II) DNA by electrophoresis on 0.8% agarose gel at 50 mA and 20 V for 17 h in the presence of 2 μg/mL chloroquine, 10 mM EDTA, 30 mM NaH2PO4, and 36 Mm Tris-HCl (pH 7.8). After electrophoresis, the gel is stained with 0.05% ethidium bromide and photographed with UV light (302 nm). The amount of DNA is quantified using a densitometer.

Cell Research:[3]
  • Cell lines: A-172, U-87, and LA-567
  • Concentrations: 0 -1000 nM
  • Incubation Time: 48 h
  • Method: MTT assay

Solubility (25°C)

In vitro

DMSO 21 mg/mL
(53.51 mM)
Water Insoluble
Ethanol Insoluble

Chemical Information

Molecular Weight 392.4
Formula

C22H20N2O5

CAS No. 86639-52-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05101096 Recruiting Drug: Sacituzumab Govitecan-hziy Advanced Solid Tumors or Triple-negative Breast Cancer Gilead Sciences October 20 2021 Phase 1|Phase 2
NCT04866641 Recruiting Drug: T-1201 Injection 100 mg Kit Advanced Solid Tumor Taivex Therapeutics Corporation June 24 2021 Phase 1
NCT04617522 Recruiting Drug: Sacituzumab Govitecan-hziy Advanced or Metastatic Solid Tumor|Liver Failure Gilead Sciences April 6 2021 Phase 1
NCT03995706 Recruiting Drug: Sacituzumab Govitecan Glioblastoma The University of Texas Health Science Center at San Antonio|Gilead Sciences July 17 2019 Early Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy SN-38 | SN-38 supplier | purchase SN-38 | SN-38 cost | SN-38 manufacturer | order SN-38 | SN-38 distributor